Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

Aging is associated with an increasing burden of morbidity, especially for cardiovascular
diseases (CVDs). General cardiovascular risk factors, ischemic heart diseases, heart failure …

Cardiac arrhythmias remain a common cause of death and disability. Antiarrhythmic drugs
(AADs) and antiarrhythmic agents remain a cornerstone of current cardiac arrhythmia …

Importance Aspirin is an effective and low-cost option for reducing atherosclerotic
cardiovascular disease (CVD) events and improving mortality rates among individuals with …

This review explores the concept of synergy in pharmacology, emphasizing its importance in
optimizing treatment outcomes through the combination of drugs with different mechanisms …

About 18 million deaths occur due to cardiovascular diseases each year, of which 80% are
in low-income and middle-income countries, 1 and three times as many individuals have …

Non-adherence to medication is a global health problem with far-reaching individual-level
and population-level consequences but remains unappreciated and under-addressed in the …

Cardiovascular diseases (CVD) remain the leading cause of death worldwide, and
pharmacotherapy of most of them is suboptimal. Thus, there is a clear unmet clinical need to …

Glucagon-like peptide-1 receptor (GLP-1R) is a critical therapeutic target for type 2 diabetes
mellitus (T2DM). The GLP-1R cellular signaling mechanism relevant to insulin secretion and …

Atherosclerotic cardiovascular disease (ASCVD) is a prevalent chronic condition managed
through pharmacotherapy targeting modifiable risk factors. However, ASCVD patients often …